Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

NCT04792502 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT04792502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04792502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Recruiting
Start date
July 14, 2022
Completion date
August 31, 2027
Enrollment
52 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, follicular lymphoma, marginal zone lymphoma